Uncovering the changing treatment landscape for low-risk prostate cancer in the usa from 2010 to 2020 : insights from the national cancer data base
Edoardo Beatrici, Muhieddine Labban, Benjamin V. Stone, Dejan K. Filipas, Leonardo O. Reis, Giovanni Lughezzani, Nicolò M. Buffi, Adam S. Kibel, Alexander P. Cole, Quoc-Dien Trinh
EDITORIAL
Inglês
Agradecimentos: Quoc-Dien Trinh certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock...
Ver mais
Agradecimentos: Quoc-Dien Trinh certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Quoc-Dien Trinh: reports consulting fees from Astellas, Bayer, and Janssen, and research funding from the American Cancer Society and Pfizer Global Medical Grants. Alexander P. Cole reports research funding from the American Cancer Society and Pfizer Global Medical Grants and a Bruce A. & Robert L. Beal Research Fellowship from the Department of Surgery, Brigham and Women’s Hospital. Leonardo O. Reis: is supported by research funding from a J. William Fulbright Foreign Scholarship and the Brazilian National Council for Scientific and Technological Development (CNPq Research Productivity 304747/2018-1 and 310135/2022-2). The remaining authors have nothing to disclose
Ver menos
Abstract: The management of prostate cancer (PCa) has evolved from a paradigm of "treat when caught early" to "treat only when necessary". Despite inconsistency in its use, active surveillance has evolved over the past two decades into the gold standard for management of low-risk PCa. Our objective...
Ver mais
Abstract: The management of prostate cancer (PCa) has evolved from a paradigm of "treat when caught early" to "treat only when necessary". Despite inconsistency in its use, active surveillance has evolved over the past two decades into the gold standard for management of low-risk PCa. Our objective was to investigate whether the use of expectant management (active surveillance, watchful waiting, no treatment) as a first-line approach for low-risk PCa has increased over the past decade. We queried the US National Cancer Data Base for men diagnosed with localized PCa between 2010 and 2020. Two multivariable logistic regression models with different two-way interaction terms (year of diagnosis × D'Amico risk classification, and year of diagnosis × International Society of Urological Pathology [ISUP] grade group) were fitted to predict the probability of undergoing expectant management versus active treatment. The predicted probability of expectant management increased from 13.7% in 2010 to 64.4% in 2020 for men with low-risk PCa, and from 12.9% in 2010 to 61.6% in 2020 for ISUP grade group 1 PCa (both pinteraction < 0.001). The frequency of expectant management for low-risk PCa has increased dramatically during the past decade. We expect this trend to further increase owing to the growing awareness of the harms of overtreatment of indolent disease. PATIENT SUMMARY: We examined the use of expectant management for prostate cancer between 2010 and 2020 in a large hospital-based registry from the USA. We found that the proportion of men receiving expectant management for low-risk prostate cancer is increasing. We conclude that growing awareness of the harms of overtreatment has profoundly affected trends for prostate cancer treatment in the USA
Ver menos
CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPQ
304747/2018-1; 310135/2022-2
Fechado
Uncovering the changing treatment landscape for low-risk prostate cancer in the usa from 2010 to 2020 : insights from the national cancer data base
Edoardo Beatrici, Muhieddine Labban, Benjamin V. Stone, Dejan K. Filipas, Leonardo O. Reis, Giovanni Lughezzani, Nicolò M. Buffi, Adam S. Kibel, Alexander P. Cole, Quoc-Dien Trinh
Uncovering the changing treatment landscape for low-risk prostate cancer in the usa from 2010 to 2020 : insights from the national cancer data base
Edoardo Beatrici, Muhieddine Labban, Benjamin V. Stone, Dejan K. Filipas, Leonardo O. Reis, Giovanni Lughezzani, Nicolò M. Buffi, Adam S. Kibel, Alexander P. Cole, Quoc-Dien Trinh
Fontes
European urology (Fonte avulsa) |